cadherin related 23Genealiases: CDHR23 · PITA5 · USH1D
Q-omics provides the consensus-scored CDH23 profile across patient tissues and cancer cell-line models. CDH23 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDH23 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CDH23 RNA expression shows 14,095 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where CDH23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH23 survival associations across molecular data types. CDH23 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (13) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH23 RNA expression–survival associations across cancer types. High CDH23 expression shows unfavorable associations in LGG, but favorable associations in ACC, SKCM, HNSC, LIHC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDH23 RNA expression.
This table summarizes CDH23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CDH23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH23 shows lower tumor expression in LUAD, COAD, UCEC, BRCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher CDH23 RNA expression in tumor versus normal tissue (log2 FC = +0.775, t-test p < 0.001).
This table shows molecular features associated with CDH23 in patient tissues and cancer cell lines. In patient samples, CDH23 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
